lobbying_activities: 1879669
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
This data as json
| id | filing_uuid | filing_type | registrant_name | registrant_id | client_name | filing_year | filing_period | issue_code | specific_issues | government_entities | income_amount | expense_amount | is_no_activity | is_termination | received_date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1879669 | 04a6d35d-4b18-4e77-8510-2369473e5b70 | Q3 | RED+BLUE STRATEGIES | 400693064 | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) | 2016 | third_quarter | PHA | H.R. 5327 Continuing Resolution for Appropriations and Military Construction, VA and Related Agencies Act of 2017 and Zika Response and Preparedness Act - issues related to opioid issues and other prescription drug - related policies. The Comprehensive Addiction and Recovery Act(S. 524) - Legislation focused on fighting the opioid epidemic in America, including amendments allowing the use of certain pharmacies and providers to protect Medicare beneficiaries from addiction. H.R. 2646- The Helping Families in Mental Health Crisis Act - Issues related to prescription drug coverage and benefits. The Mental Health Reform Act of 2015 (S. 1945) - Legislation focused on improving treatment for mental health and substance use disorders. Particular focus on formulary policies. H.R. 244 - The MAC Transparency Act. Clarifying current policies on pricing transparency for prescription drugs that exist under current law and regulatory policies. Implementation of the health reform law with a focus on policies and regulations related to biosimilars, prescription drug coverage in the Exchanges and related policies. Policies related to Medicare Part C and D with a focus on network design, formularies and access to specialty medications. Issues related to Senate Finance Committee activity on advances in chronic care with a focus on medication-based therapies. Work focused on Medicare Part D and related regulations and reports specific to pharmacy networks. Issues related to the implementation of the health care law that impact public and private sector pharmacy benefits. Issues related to pricing and access to prescription drugs including specialty drugs and biosimilars. | Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2016-10-17T14:37:31.120000-04:00 |